Tagged: investment research

What Investors Need to Know

Hologic (HOLX) closed the latest trading day at $70.94, indicating a -0.24% change from the previous session’s end. This move lagged the S&P 500’s daily gain of 0.14%. Elsewhere, the Dow gained 0.3%, while the tech-heavy Nasdaq added 0.16%.

Shares of the medical device maker witnessed a gain of 1.77% over the previous month, trailing the performance of the Medical sector with its gain of 4.24% and the S&P 500’s gain of 4.89%.

Investors will be eagerly watching for the performance of Hologic in its upcoming earnings disclosure. The company’s earnings per share (EPS) are projected to be $0.94, reflecting a 12.15% decrease from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $978.36 million, indicating an 8.92% downward movement from the same quarter last year.

HOLX’s full-year Zacks Consensus Estimates are calling for earnings of $3.99 per share and revenue of $3.98 billion. These results would represent year-over-year changes of +0.76% and -1.36%, respectively.

Investors should also note any recent changes to analyst estimates for Hologic. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts’ favorable outlook on the company’s business health and profitability.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Hologic possesses a Zacks Rank of #3 (Hold).

Read the rest